20 September 2024
Marlowe plc
Total Voting Rights
In accordance with section 5.6.1 of the Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rules (DTRs), Marlowe plc ("Marlowe" or the "Group") hereby notifies the market of the following:
The Group's issued capital as at 20 September 2024 consists of 88,003,737 ordinary shares of 50p each ("Ordinary Shares") with voting rights attached. Of these, no Ordinary Shares are held exclusive of voting rights in Treasury.
Therefore, the total number of voting rights in Marlowe as at 20 September 2024 is 88,003,737.
Shareholders may use the figure of 88,003,737 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in Marlowe under the DTRs.
For further information:
| Marlowe plc | |
| Lord Ashcroft, Interim Non-Executive Chair | www.marloweplc.com |
| Adam Councell, Chief Financial Officer | Tel: +44 (0)20 3813 8498 |
| Benjamin Tucker, Head of Investor Relations & Strategy | |
| | |
| Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker) | |
| Ben Jeynes | Tel: +44 (0)20 7220 0500 |
| George Lawson | |
| | |
| Investec Bank plc (Joint Broker) | |
| Henry Reast | Tel: +44 (0)20 7597 5970 |
| Oliver Cardigan | |
| | |
| FTI Consulting | |
| Nick Hasell | Tel: +44 (0)20 3727 1340 |
| Alex Le May | |
About Marlowe plc
Marlowe is a leader in business-critical services which ensures compliance with strict regulations and insurance requirements across Fire Safety & Security, Water & Air Hygiene and Occupational Health. The Group has a national footprint and serves over 30,000 customers across office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
